SlideShare a Scribd company logo
MiniSpheres™
Oral Drug Delivery Platform for High and Bulky Dose
MiniSpheres™ are LATITUDE Pharmaceuticals Inc.’s new oral drug delivery technology
especially suited for high/bulky dose and/or sustained release applications. MiniSpheres™ are
tiny spherical pellets (~0.5 to 1.5 mm diameter) that can be dispensed in a packet or a bottle.
Unlike bulky tablets, MiniSpheres™ are very easy to swallow – even in large quantities –
because of their small, spherical, smooth shape. For oral dosing, the pellets may be sprinkled
on food or mixed with water or flavored liquids to form a drinkable oral suspension, which may
be ideal for pediatric applications and for patients with swallowing difficulties. Multi-gram dos-
ing is possible with this approach. For low-dose drugs, the MiniSpheres™ may be dispensed in
capsules.
Despite their small size, MiniSpheres™ can provide a sustained release profile – up to 24
hours in vitro – even for highly water-soluble drugs. The release profile is adjustable to meet
most any dosing requirements. If needed, the taste-masking agents may be incorporated
during their production.
LATITUDE Pharmaceuticals, Inc. | 9675 Businesspark Ave, San Diego, CA 92131 | Tel: 858-546-0924 | Fax: 858-546-0958 | www.latitudepharma.com
Key Features of MiniSpheres™
 Ideal for high dose (>1-2 grams) drugs
 Applicable for insoluble and highly water soluble drugs,
nutraceuticals, and vitamins
 Converts multiple dosing/day to compliance-enhancing
once/day format
 Simple manufacturing process
 Manufacturable using conventional equipment
 Low cost of goods
 Patent pending

More Related Content

Viewers also liked

A supervised lung nodule classification method using patch based context anal...
A supervised lung nodule classification method using patch based context anal...A supervised lung nodule classification method using patch based context anal...
A supervised lung nodule classification method using patch based context anal...
ASWATHY VG
 
NXT
NXTNXT
USP <1116> and its impact on Microbiology
USP <1116> and its impact on MicrobiologyUSP <1116> and its impact on Microbiology
USP <1116> and its impact on Microbiology
Tim Sandle, Ph.D.
 
Image Processing Based Signature Recognition and Verification Technique Using...
Image Processing Based Signature Recognition and Verification Technique Using...Image Processing Based Signature Recognition and Verification Technique Using...
Image Processing Based Signature Recognition and Verification Technique Using...
Priyanka Pradhan
 
sejarah produksi dokumenter
sejarah produksi dokumentersejarah produksi dokumenter
sejarah produksi dokumenter
Restu Putra Tegar Tegar
 
New trends of ketamine consumption in europe
New trends of ketamine consumption in europeNew trends of ketamine consumption in europe
New trends of ketamine consumption in europe
Universitat Autònoma de Barcelona.
 

Viewers also liked (7)

Hosts
HostsHosts
Hosts
 
A supervised lung nodule classification method using patch based context anal...
A supervised lung nodule classification method using patch based context anal...A supervised lung nodule classification method using patch based context anal...
A supervised lung nodule classification method using patch based context anal...
 
NXT
NXTNXT
NXT
 
USP <1116> and its impact on Microbiology
USP <1116> and its impact on MicrobiologyUSP <1116> and its impact on Microbiology
USP <1116> and its impact on Microbiology
 
Image Processing Based Signature Recognition and Verification Technique Using...
Image Processing Based Signature Recognition and Verification Technique Using...Image Processing Based Signature Recognition and Verification Technique Using...
Image Processing Based Signature Recognition and Verification Technique Using...
 
sejarah produksi dokumenter
sejarah produksi dokumentersejarah produksi dokumenter
sejarah produksi dokumenter
 
New trends of ketamine consumption in europe
New trends of ketamine consumption in europeNew trends of ketamine consumption in europe
New trends of ketamine consumption in europe
 

Similar to Minispheres

Tablets
TabletsTablets
Tablets
Teny Thomas
 
TABLETS
TABLETS TABLETS
TABLETS
Teny Thomas
 
Multiparticulate drugdeliverysystems
Multiparticulate drugdeliverysystemsMultiparticulate drugdeliverysystems
Multiparticulate drugdeliverysystems
Dr Gajanan Sanap
 
bABE STUDIES
bABE STUDIESbABE STUDIES
bABE STUDIES
phanigvd
 
Pharmaceutical powders
Pharmaceutical powdersPharmaceutical powders
Pharmaceutical powders
Ambedkar Niper
 
Tablets
TabletsTablets
Introduction to dosage forms
Introduction to dosage formsIntroduction to dosage forms
Introduction to dosage forms
Bhagyashri Gawade
 
Dosage Forms and Drug Delivery Systems
Dosage Forms and Drug Delivery SystemsDosage Forms and Drug Delivery Systems
Dosage Forms and Drug Delivery Systems
SANI SINGH
 
introduction to dosages form
introduction to dosages formintroduction to dosages form
introduction to dosages form
PRiyanka Kkumari
 
ORAL ROUTE OF DRUG ADMINISTRATION_Dr. Jeenal Mistry.pdf
ORAL ROUTE OF DRUG ADMINISTRATION_Dr. Jeenal Mistry.pdfORAL ROUTE OF DRUG ADMINISTRATION_Dr. Jeenal Mistry.pdf
ORAL ROUTE OF DRUG ADMINISTRATION_Dr. Jeenal Mistry.pdf
Dr Jeenal Mistry
 
Powder presentation
Powder presentationPowder presentation
Powder presentation
DrxShubhanshuRsJaisw
 
PillPower The Art and Science of Pharmaceutical Tablets. pptx.
PillPower The Art and Science of Pharmaceutical Tablets. pptx.PillPower The Art and Science of Pharmaceutical Tablets. pptx.
PillPower The Art and Science of Pharmaceutical Tablets. pptx.
Whahidul Hasan
 
tablets-160607084805 (1).pdf
tablets-160607084805 (1).pdftablets-160607084805 (1).pdf
tablets-160607084805 (1).pdf
SKFPP
 
Tablets - Pharmaceutics
Tablets - PharmaceuticsTablets - Pharmaceutics
Tablets - Pharmaceutics
Areej Abu Hanieh
 
introduction of tablet and evalution
introduction of tablet and evalutionintroduction of tablet and evalution
introduction of tablet and evalution
pooja joshi
 
Tablets medicinal by adk
 Tablets medicinal by adk Tablets medicinal by adk
Tablets medicinal by adk
Adarsh Khilawdiya
 
PH 1.3 Drug Formulations & Drug Delivery Systems (1).pptx
PH 1.3 Drug Formulations & Drug Delivery Systems (1).pptxPH 1.3 Drug Formulations & Drug Delivery Systems (1).pptx
PH 1.3 Drug Formulations & Drug Delivery Systems (1).pptx
Vyomakesh raju
 
121725101002-Mini tablets.pptx
121725101002-Mini tablets.pptx121725101002-Mini tablets.pptx
121725101002-Mini tablets.pptx
TridevSastri1
 

Similar to Minispheres (20)

Tablets
TabletsTablets
Tablets
 
TABLETS
TABLETS TABLETS
TABLETS
 
Multiparticulate drugdeliverysystems
Multiparticulate drugdeliverysystemsMultiparticulate drugdeliverysystems
Multiparticulate drugdeliverysystems
 
Review article
Review articleReview article
Review article
 
bABE STUDIES
bABE STUDIESbABE STUDIES
bABE STUDIES
 
Pharmaceutical powders
Pharmaceutical powdersPharmaceutical powders
Pharmaceutical powders
 
Tablets
TabletsTablets
Tablets
 
Introduction to dosage forms
Introduction to dosage formsIntroduction to dosage forms
Introduction to dosage forms
 
Dosage Forms and Drug Delivery Systems
Dosage Forms and Drug Delivery SystemsDosage Forms and Drug Delivery Systems
Dosage Forms and Drug Delivery Systems
 
introduction to dosages form
introduction to dosages formintroduction to dosages form
introduction to dosages form
 
ORAL ROUTE OF DRUG ADMINISTRATION_Dr. Jeenal Mistry.pdf
ORAL ROUTE OF DRUG ADMINISTRATION_Dr. Jeenal Mistry.pdfORAL ROUTE OF DRUG ADMINISTRATION_Dr. Jeenal Mistry.pdf
ORAL ROUTE OF DRUG ADMINISTRATION_Dr. Jeenal Mistry.pdf
 
Powder presentation
Powder presentationPowder presentation
Powder presentation
 
PillPower The Art and Science of Pharmaceutical Tablets. pptx.
PillPower The Art and Science of Pharmaceutical Tablets. pptx.PillPower The Art and Science of Pharmaceutical Tablets. pptx.
PillPower The Art and Science of Pharmaceutical Tablets. pptx.
 
tab new
tab newtab new
tab new
 
tablets-160607084805 (1).pdf
tablets-160607084805 (1).pdftablets-160607084805 (1).pdf
tablets-160607084805 (1).pdf
 
Tablets - Pharmaceutics
Tablets - PharmaceuticsTablets - Pharmaceutics
Tablets - Pharmaceutics
 
introduction of tablet and evalution
introduction of tablet and evalutionintroduction of tablet and evalution
introduction of tablet and evalution
 
Tablets medicinal by adk
 Tablets medicinal by adk Tablets medicinal by adk
Tablets medicinal by adk
 
PH 1.3 Drug Formulations & Drug Delivery Systems (1).pptx
PH 1.3 Drug Formulations & Drug Delivery Systems (1).pptxPH 1.3 Drug Formulations & Drug Delivery Systems (1).pptx
PH 1.3 Drug Formulations & Drug Delivery Systems (1).pptx
 
121725101002-Mini tablets.pptx
121725101002-Mini tablets.pptx121725101002-Mini tablets.pptx
121725101002-Mini tablets.pptx
 

Recently uploaded

Elizabeth Buie - Older adults: Are we really designing for our future selves?
Elizabeth Buie - Older adults: Are we really designing for our future selves?Elizabeth Buie - Older adults: Are we really designing for our future selves?
Elizabeth Buie - Older adults: Are we really designing for our future selves?
Nexer Digital
 
Microsoft - Power Platform_G.Aspiotis.pdf
Microsoft - Power Platform_G.Aspiotis.pdfMicrosoft - Power Platform_G.Aspiotis.pdf
Microsoft - Power Platform_G.Aspiotis.pdf
Uni Systems S.M.S.A.
 
GridMate - End to end testing is a critical piece to ensure quality and avoid...
GridMate - End to end testing is a critical piece to ensure quality and avoid...GridMate - End to end testing is a critical piece to ensure quality and avoid...
GridMate - End to end testing is a critical piece to ensure quality and avoid...
ThomasParaiso2
 
20240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 202420240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 2024
Matthew Sinclair
 
Alt. GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using ...
Alt. GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using ...Alt. GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using ...
Alt. GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using ...
James Anderson
 
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
Neo4j
 
Generative AI Deep Dive: Advancing from Proof of Concept to Production
Generative AI Deep Dive: Advancing from Proof of Concept to ProductionGenerative AI Deep Dive: Advancing from Proof of Concept to Production
Generative AI Deep Dive: Advancing from Proof of Concept to Production
Aggregage
 
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfObservability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Paige Cruz
 
UiPath Test Automation using UiPath Test Suite series, part 5
UiPath Test Automation using UiPath Test Suite series, part 5UiPath Test Automation using UiPath Test Suite series, part 5
UiPath Test Automation using UiPath Test Suite series, part 5
DianaGray10
 
By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024
Pierluigi Pugliese
 
Epistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI supportEpistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI support
Alan Dix
 
Pushing the limits of ePRTC: 100ns holdover for 100 days
Pushing the limits of ePRTC: 100ns holdover for 100 daysPushing the limits of ePRTC: 100ns holdover for 100 days
Pushing the limits of ePRTC: 100ns holdover for 100 days
Adtran
 
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
Neo4j
 
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
Neo4j
 
20240607 QFM018 Elixir Reading List May 2024
20240607 QFM018 Elixir Reading List May 202420240607 QFM018 Elixir Reading List May 2024
20240607 QFM018 Elixir Reading List May 2024
Matthew Sinclair
 
GraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge GraphGraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge Graph
Guy Korland
 
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptx
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptxSecstrike : Reverse Engineering & Pwnable tools for CTF.pptx
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptx
nkrafacyberclub
 
A tale of scale & speed: How the US Navy is enabling software delivery from l...
A tale of scale & speed: How the US Navy is enabling software delivery from l...A tale of scale & speed: How the US Navy is enabling software delivery from l...
A tale of scale & speed: How the US Navy is enabling software delivery from l...
sonjaschweigert1
 
DevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA ConnectDevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA Connect
Kari Kakkonen
 
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdfFIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance
 

Recently uploaded (20)

Elizabeth Buie - Older adults: Are we really designing for our future selves?
Elizabeth Buie - Older adults: Are we really designing for our future selves?Elizabeth Buie - Older adults: Are we really designing for our future selves?
Elizabeth Buie - Older adults: Are we really designing for our future selves?
 
Microsoft - Power Platform_G.Aspiotis.pdf
Microsoft - Power Platform_G.Aspiotis.pdfMicrosoft - Power Platform_G.Aspiotis.pdf
Microsoft - Power Platform_G.Aspiotis.pdf
 
GridMate - End to end testing is a critical piece to ensure quality and avoid...
GridMate - End to end testing is a critical piece to ensure quality and avoid...GridMate - End to end testing is a critical piece to ensure quality and avoid...
GridMate - End to end testing is a critical piece to ensure quality and avoid...
 
20240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 202420240605 QFM017 Machine Intelligence Reading List May 2024
20240605 QFM017 Machine Intelligence Reading List May 2024
 
Alt. GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using ...
Alt. GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using ...Alt. GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using ...
Alt. GDG Cloud Southlake #33: Boule & Rebala: Effective AppSec in SDLC using ...
 
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024GraphSummit Singapore | The Art of the  Possible with Graph - Q2 2024
GraphSummit Singapore | The Art of the Possible with Graph - Q2 2024
 
Generative AI Deep Dive: Advancing from Proof of Concept to Production
Generative AI Deep Dive: Advancing from Proof of Concept to ProductionGenerative AI Deep Dive: Advancing from Proof of Concept to Production
Generative AI Deep Dive: Advancing from Proof of Concept to Production
 
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdfObservability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
Observability Concepts EVERY Developer Should Know -- DeveloperWeek Europe.pdf
 
UiPath Test Automation using UiPath Test Suite series, part 5
UiPath Test Automation using UiPath Test Suite series, part 5UiPath Test Automation using UiPath Test Suite series, part 5
UiPath Test Automation using UiPath Test Suite series, part 5
 
By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024By Design, not by Accident - Agile Venture Bolzano 2024
By Design, not by Accident - Agile Venture Bolzano 2024
 
Epistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI supportEpistemic Interaction - tuning interfaces to provide information for AI support
Epistemic Interaction - tuning interfaces to provide information for AI support
 
Pushing the limits of ePRTC: 100ns holdover for 100 days
Pushing the limits of ePRTC: 100ns holdover for 100 daysPushing the limits of ePRTC: 100ns holdover for 100 days
Pushing the limits of ePRTC: 100ns holdover for 100 days
 
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
GraphSummit Singapore | Enhancing Changi Airport Group's Passenger Experience...
 
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
GraphSummit Singapore | The Future of Agility: Supercharging Digital Transfor...
 
20240607 QFM018 Elixir Reading List May 2024
20240607 QFM018 Elixir Reading List May 202420240607 QFM018 Elixir Reading List May 2024
20240607 QFM018 Elixir Reading List May 2024
 
GraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge GraphGraphRAG is All You need? LLM & Knowledge Graph
GraphRAG is All You need? LLM & Knowledge Graph
 
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptx
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptxSecstrike : Reverse Engineering & Pwnable tools for CTF.pptx
Secstrike : Reverse Engineering & Pwnable tools for CTF.pptx
 
A tale of scale & speed: How the US Navy is enabling software delivery from l...
A tale of scale & speed: How the US Navy is enabling software delivery from l...A tale of scale & speed: How the US Navy is enabling software delivery from l...
A tale of scale & speed: How the US Navy is enabling software delivery from l...
 
DevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA ConnectDevOps and Testing slides at DASA Connect
DevOps and Testing slides at DASA Connect
 
FIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdfFIDO Alliance Osaka Seminar: Overview.pdf
FIDO Alliance Osaka Seminar: Overview.pdf
 

Minispheres

  • 1. MiniSpheres™ Oral Drug Delivery Platform for High and Bulky Dose MiniSpheres™ are LATITUDE Pharmaceuticals Inc.’s new oral drug delivery technology especially suited for high/bulky dose and/or sustained release applications. MiniSpheres™ are tiny spherical pellets (~0.5 to 1.5 mm diameter) that can be dispensed in a packet or a bottle. Unlike bulky tablets, MiniSpheres™ are very easy to swallow – even in large quantities – because of their small, spherical, smooth shape. For oral dosing, the pellets may be sprinkled on food or mixed with water or flavored liquids to form a drinkable oral suspension, which may be ideal for pediatric applications and for patients with swallowing difficulties. Multi-gram dos- ing is possible with this approach. For low-dose drugs, the MiniSpheres™ may be dispensed in capsules. Despite their small size, MiniSpheres™ can provide a sustained release profile – up to 24 hours in vitro – even for highly water-soluble drugs. The release profile is adjustable to meet most any dosing requirements. If needed, the taste-masking agents may be incorporated during their production. LATITUDE Pharmaceuticals, Inc. | 9675 Businesspark Ave, San Diego, CA 92131 | Tel: 858-546-0924 | Fax: 858-546-0958 | www.latitudepharma.com Key Features of MiniSpheres™  Ideal for high dose (>1-2 grams) drugs  Applicable for insoluble and highly water soluble drugs, nutraceuticals, and vitamins  Converts multiple dosing/day to compliance-enhancing once/day format  Simple manufacturing process  Manufacturable using conventional equipment  Low cost of goods  Patent pending